Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q2 2025
Maravai Lifesciences Holdings (MRVI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Maravai Lifesciences Holdings (MRVI) reported revenue of $47.4M for the second quarter 2025 (Q2 2025), -32% from a year earlier and +1% from the quarter before. Operating margin was -139.8%, net loss $69.8M (147.3% of revenue).
Maravai Lifesciences Holdings, Q2 2025: revenue $47.4M (-32% year over year), operating margin -139.8%, net loss $69.8M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $47.4M | +1% | -32% |
| Operating profit | −$66.3M | — | — |
| Net earnings | −$69.8M | — | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $47.4M in Q2 2025, down 32% year over year and up 1% from the previous quarter. Nucleic Acid Production was the largest line at 66% of revenue. Nucleic Acid Production lost $23.5M year over year (down 43%), 107% of the total change.
Gross margin was 16.4%. Operating costs exceeded revenue by $66.3M, an operating margin of -139.8%. The quarter ended with a net loss of $69.8M, wider than the previous quarter's $52.9M loss. Minority interests bore $30.2M of it: to shareholders the quarter was a loss of $39.6M.
Operating cash flow was −$10.3M. Non-cash charges added back $13.2M of depreciation and amortization and $6.8M of share-based compensation. Working capital and other items added $39.6M. Capital expenditures of $2.9M exceeded it, leaving free cash flow of −$13.1M.
Questions
What was Maravai Lifesciences Holdings' revenue in the second quarter 2025?
Maravai Lifesciences Holdings (MRVI) reported revenue of $47.4M for the second quarter 2025 (Q2 2025), -32% from a year earlier and +1% from the quarter before.
Was Maravai Lifesciences Holdings profitable in the second quarter 2025?
Operating loss was $66.3M (-139.8% of revenue) and net loss $69.8M.